GSK licenses HUTCHMED cancer therapy HMPL-A830 in deal worth up to $1.295bn

The agreement gives GSK worldwide rights outside Greater China to develop and commercialise HUTCHMED's first-in-class KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830.

HUTCHMED will receive $110 million upfront and is eligible for a further $1.185 billion in development, regulatory and commercial milestones, taking the potential deal value to $1.295 billion, plus tiered royalties.

HMPL-A830 is expected to enter clinical development in the second half of 2026, initially targeting colorectal, pancreatic and lung cancers with KRAS alterations.

Field	Content
Alert Type	Deal
Companies	GSK; HUTCHMED
Deal Type	Exclusive development and licence agreement
Asset or Company	HMPL-A830
Therapy Area(s)	Oncology; colorectal cancer; pancreatic cancer; lung cancer
Technology or Modality	KRAS-EGFR antibody-targeted therapy conjugate
Deal Value	Up to $1.295 billion, including $110 million upfront and up to $1.185 billion in development, regulatory and commercial milestone payments, plus tiered royalties
Development Stage	Preclinical / preparing for Phase I clinical development
Geography	Worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan
What Happened	GSK secured exclusive development and commercialisation rights outside Greater China to HUTCHMED's HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate.
Why It Matters	The transaction gives GSK access to a novel precision-oncology platform designed to deliver a KRAS inhibitor directly to EGFR-expressing tumours while simultaneously blocking EGFR and KRAS signalling.
Supporting Context	HUTCHMED expects global Phase I development of HMPL-A830 to begin in the second half of 2026, initially focusing on colorectal, pancreatic and lung cancers.
Strategic Rationale	GSK gains a differentiated KRAS-targeted oncology candidate while HUTCHMED retains development and commercialisation rights in Greater China.
Potential Impact	If successful, HMPL-A830 could provide a new targeted approach for patients with KRAS-altered tumours that remain difficult to treat with existing therapies.
Key Takeaway	GSK is committing up to $1.295 billion for ex-Greater China rights to HUTCHMED's novel KRAS-EGFR oncology candidate HMPL-A830.
What to Watch	Initiation of the global Phase I programme and early clinical evidence for HMPL-A830 in KRAS-altered solid tumours.
Primary Source	HUTCHMED
Relevant Date	3 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com